Taiwan University comparator) evaluated for drug effectiveness Comparator: NA Hospital, Taipei, before surgery, 6 patients P2 Taiwan showed typical heartburn but their endoscopic findings were normal Turner et al. () 198 pH studies (148 studies Case series Inclusion: Index test: Technical efficacy Division of had enough data to be Not stated System: Bravo™ wireless capsule system Early detachment Gastroenterology, included) Level: IV Exclusion: Insertion: (during endoscopy) Insufficient data capture Brigham and Off medical therapy: 115 Quality: Q2 Not stated Placement: 6 cm above the SCJ Day-to-day variability in Women’s Hospital, patients, 76 females, 39 males. oesophageal acid CX (no Duration: 48 hours Boston, Mean age: 50 ± 13 years exposure comparator) Comparator: Massachusetts, On medical therapy: 33 P2 USA System: Bravo™ wireless capsule system patients, 26 females, 7 males. Insertion: transnasally Mean age: 52 ± 14 years Placement: Indications: Duration: 24 hours Typical and atypical symptoms of GORD or persistent symptoms despite medical therapy. Patients with planned anti-reflux surgery were also evaluated Ward et al. () Case series 60 patients (58 patients had Inclusion: Index test: Technical efficacy: enough data to be included) Not stated System: Bravo™ wireless capsule system Attachment failure Division of 26 males, 34 females Gastroenterology Level: IV Exclusion: Insertion: transorally Hardware malfunction and Hepatology, Mean age: 54 years (range Quality: Q2 Not stated Placement: 6 cm above the SCJ Mayo Clinic, CX (no Duration: 48 hours Jacksonville, Indications: comparator) Comparator: NA Florida, USA Document GORD before P2 surgery, possible GORD with negative PPI trial, evaluate response to PPI, possible supra-oesophageal GORD, non-cardiac chest pain, evaluate response to Stretta
Taiwan University Hospital, Taipei, Taiwan comparator) P2 evaluated for drug effectiveness before surgery, 6 patients showed typical heartburn but their endoscopic findings were normal Comparator: NA Turner et al. () Division of Gastroenterology, Brigham and Women’s Hospital, Boston, Massachusetts, USA Case series Level: IV Quality: Q2 CX (no comparator) P2 198 pH studies (148 studies had enough data to be included) Off medical therapy: 115 patients, 76 females, 39 males. Mean age: 50 ± 13 years On medical therapy: 33 patients, 26 females, 7 males. Mean age: 52 ± 14 years Indications: Typical and atypical symptoms of GORD or persistent symptoms despite medical therapy. Patients with planned anti-reflux surgery were also evaluated Inclusion: Not stated Exclusion: Not stated Index test: System: Bravo™ wireless capsule system Insertion: (during endoscopy) Placement: 6 cm above the SCJ Duration: 48 hours Comparator: System: Bravo™ wireless capsule system Insertion: transnasally Placement: Duration: 24 hours Technical efficacy Early detachment Insufficient data capture Day-to-day variability in oesophageal acid exposure Ward et al. () Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA Case series Level: IV Quality: Q2 CX (no comparator) P2 60 patients (58 patients had enough data to be included) 26 males, 34 females Mean age: 54 years (range Indications: Document GORD before surgery, possible GORD with negative PPI trial, evaluate response to PPI, possible supra-oesophageal GORD, non-cardiac chest pain, evaluate response to Stretta Inclusion: Not stated Exclusion: Not stated Index test: System: Bravo™ wireless capsule system Insertion: transorally Placement: 6 cm above the SCJ Duration: 48 hours Comparator: NA Technical efficacy: Attachment failure Hardware malfunction
1203-ContractedAssessmentReport-Catheter-free%20ambulatory%20pH%20test%20for%20GORD%20accessible.docx